molmed

News & Events

Stay update

Case Study: MolMed Presents Process Development and Large-Scale CMP Production for Lentiviral (LV) Vectors ▾

Case Study: MolMed Presents Process Development and Large-Scale CMP Production for Lentiviral (LV) Vectors

MolMed organizes a webinar, with the collaboration of Phacilitate, entitled "Case Study: MolMed Presents Process Development and LargeScale GMP Production for Lentiviral (LV) Vectors" conducted by:

Luca Alberici, Chief Business Officer
Margherita Neri, Up-Stream Process Development Manager
Francesca Bellintani, Down-Stream Process Development Manager

News & Events

Stay update

COVID-19 impacting Cell&Gene therapy manufacturing Webinar ▾

COVID-19 impacting Cell&Gene therapy manufacturing Webinar

Luca Alberici, MolMed CBO, participates in the "COVID-19 impacting Cell & Gene therapy manufacturing webinar" organized by Bakery & Aseptic Technologies

News & Events

Stay update

Virtual Meeting ASGCT 2020 ▾

Virtual Meeting ASGCT 2020

Giuliana Vallanti, MolMed's Process Development & Quality Control Director, participates in the ASGCT 2020 Virtual Meeting in collaboration with Pall Corporation

News & Events

Stay update

Cell&Gene Therapy Virtual Symposium 2020 ▾

Cell&Gene Therapy Virtual Symposium 2020

Luca Alberici, MolMed CBO, participates in the "Cell and Gene Therapy Virtual Symposium 2020" organized by Bio-Techne

Investors

Publication of the Minutes (in Italian) of the OGM held on April 27, 2020

Publication of the Minutes (in Italian) of the OGM held on April 27, 2020 ▾

Investors

Minutes (in Italian) of the OGM held on April 27, 2020

Minutes (in Italian) of the OGM held on April 27, 2020 ▾

Investors

Annual Financial Report at December 31, 2019 (English translation for convenience)

Annual Financial Report at December 31, 2019 (English translation for convenience) ▾

Investors

Interim Management Report at March 31st, 2020

Interim Management Report at March 31st, 2020 ▾

Investors

Update on the timing for the approval of ACG Offer Document

Update on the timing for the approval of ACG Offer Document ▾

Investors

MolMed Board of Directors approves first quarter 2020 financial results

MolMed Board of Directors approves first quarter 2020 financial results ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.